Natural Management of Constipation
Evidence-based natural approaches to chronic constipation including kiwifruit, magnesium oxide, psyllium fiber, and targeted probiotics — backed by RCTs and meta-analyses
Chronic constipation affects roughly one in seven adults worldwide — defined as fewer than three bowel movements per week, or ongoing straining, hard stools, or a feeling of incomplete evacuation. Pharmaceutical laxatives provide short-term relief but carry risks of dependence and gut flora disruption with extended use. Several natural interventions have strong clinical trial evidence: kiwifruit rivals psyllium in head-to-head trials [1][2], magnesium oxide achieves a 70% response rate in randomized trials [3], probiotics increase stool frequency by over one movement per week on average [4], and dietary fiber produces meaningful relief in two-thirds of people who try it [5].
How Constipation Develops
The colon's job is to absorb water and electrolytes from digested food while coordinating muscular contractions — peristalsis — to move material toward the rectum. Constipation arises when this process is too slow, producing dry, hard stools that are difficult to pass. Several mechanisms contribute:
- Slow colonic transit: Peristaltic contractions are too weak or infrequent; stool spends too long in the colon and becomes excessively dry
- Dyssynergic defecation: The pelvic floor muscles fail to relax properly during straining, creating an outlet obstruction even when peristalsis is normal
- Low fiber intake: Inadequate dietary fiber means less bulk to stimulate peristalsis and less water retained in the stool
- Dehydration: Insufficient fluid intake leads the colon to extract more water from stool, hardening it
- Microbiome disruption: Gut bacteria produce short-chain fatty acids that directly stimulate colonic motility; dysbiosis reduces this signaling
- Medications: Opioids, iron supplements, calcium channel blockers, and many antidepressants are common pharmaceutical causes
Chronic constipation is classified as either primary (functional — no underlying disease) or secondary (caused by medication, metabolic disorders, or structural abnormalities). Natural approaches are most effective for functional constipation and can serve as useful adjuncts to medical care for secondary types.
Dietary Fiber: The Foundation
Dietary fiber is the most established intervention for chronic constipation, with decades of evidence behind it [5]. Fiber works through two complementary mechanisms:
Soluble fiber (psyllium, oats, flaxseed, legumes) absorbs water to form a soft gel that keeps stool moist and easy to pass. Psyllium husk is the most clinically studied soluble fiber for constipation. A 2022 meta-analysis of 16 RCTs across 1,251 adults found that fiber increased response rates to 66% compared to 41% in control groups, with psyllium showing the most consistent benefit of all fiber types studied [5].
Insoluble fiber (wheat bran, vegetables, whole grains) adds bulk to stool and acts as a mechanical stimulus that triggers peristaltic contractions. It is particularly effective for increasing stool frequency.
Practical guidance:
- Gradually increase fiber intake to 25–38 g/day over 2–3 weeks to avoid bloating and gas during adaptation
- Psyllium husk (1–2 tablespoons daily in a full glass of water) is the most effective single fiber supplement for constipation
- Always increase fluid intake alongside fiber — fiber without adequate water can worsen constipation
- Fiber works less well in slow-transit constipation, where the underlying problem is impaired colonic motility rather than inadequate bulk
See our Psyllium Husk page for dosing specifics.
Kiwifruit: Surprisingly Powerful Evidence
Green kiwifruit (Actinidia deliciosa) has emerged as one of the most evidence-backed foods for constipation relief, combining three distinct mechanisms: dietary fiber (pectin), an enzyme called actinidin that stimulates gastric emptying and alters intestinal digesta consistency, and osmotic effects from inositol and other compounds that retain water in the gut.
An international multicenter randomized controlled trial (Gearry et al., 2023) randomized 184 participants — including people with functional constipation, IBS-C, and healthy controls across New Zealand, Japan, and Italy — to eat 2 green kiwifruits daily or take psyllium (7.5 g/day) for 4 weeks [1]. In people with constipation, kiwifruit produced clinically relevant increases in complete spontaneous bowel movements and improvements in abdominal comfort, performing comparably to psyllium while producing fewer adverse events.
A US comparative effectiveness trial (Chey et al., 2021) directly compared kiwifruit (2/day), psyllium (12 g/day), and prunes (100 g/day) in 79 patients with chronic constipation over 4 weeks in a crossover design [2]. All three interventions significantly increased weekly complete spontaneous bowel movements. Kiwifruit uniquely improved both stool consistency (softening hard stools toward Bristol Stool Scale types 3–4) and straining scores — outcomes where psyllium and prunes were less consistent. Kiwifruit also had the smallest proportion of participants reporting digestive discomfort, making it the gentlest option of the three.
Practical use: Two whole green kiwifruits daily, ideally at breakfast or as a morning snack. Gold kiwifruit (Actinidia chinensis) shows similar benefits and is sweeter for those who find green kiwi tart.
Magnesium Oxide: Osmotic Relief
Magnesium oxide is an osmotic laxative — it draws water into the intestinal lumen, softening stool and stimulating bowel movement. Unlike stimulant laxatives such as senna or bisacodyl, it does not cause colonic nerve damage or dependence with regular use.
A double-blind, placebo-controlled RCT (Mori et al., 2019) randomized 34 women with chronic constipation to receive magnesium oxide 1.5 g/day (as 0.5 g three times daily) or matched placebo for 28 days [3]. The overall symptom response rate was 70.6% in the magnesium group versus 25.0% in placebo — a highly significant difference. Stool frequency increased, stool consistency improved from Bristol types 1–2 toward 3–4 in most responders, and radiopaque marker studies showed measurable shortening of colonic transit time.
Magnesium oxide also addresses a secondary driver of constipation in many people: magnesium deficiency. Magnesium is required for smooth muscle contraction throughout the gut, and suboptimal magnesium status impairs peristaltic coordination. Dosing for constipation (300–600 mg elemental magnesium as oxide) is higher than typical doses used for sleep or stress.
Safety note: Excessive magnesium oxide causes loose stools or diarrhea — a useful signal to reduce the dose. People with kidney disease should use magnesium supplements cautiously, as impaired renal clearance raises the risk of elevated blood magnesium. See our Magnesium page for broader context.
Probiotics: Targeting the Microbiome
The gut microbiome directly influences colonic motility through production of short-chain fatty acids (SCFAs, primarily butyrate) that fuel colonocytes and stimulate peristalsis, and through generation of bile acid metabolites and enteric neurotransmitters including serotonin and GABA that coordinate intestinal contractions via the enteric nervous system.
A 2022 systematic review and meta-analysis (van der Schoot et al.) pooled 30 probiotic RCTs (2,656 participants) and 4 synbiotic RCTs in adults with chronic constipation [4]. Key findings:
- Probiotics increased stool frequency by an average of 1.3 bowel movements per week (95% CI 0.87–1.73)
- Probiotics reduced whole gut transit time by an average of 12.4 hours (95% CI 7.2–17.6)
- Bifidobacterium strains showed the most consistent and statistically significant effects on stool frequency; Bifidobacterium lactis had particular support
- Lactobacillus casei Shirota and Bifidobacterium longum also demonstrated significant benefits in individual trials
- Synbiotics (probiotic plus prebiotic fiber) performed comparably to standalone probiotics
For chronic constipation, Bifidobacterium-dominant formulas are preferred over Lactobacillus-only products based on this evidence. A combined approach — probiotic supplement alongside adequate prebiotic fiber — is rational.
See our Probiotics page for strain selection guidance.
Prunes: Fiber, Sorbitol, and Phenolics
Prunes (dried plums) deserve attention as a whole-food intervention with clinical evidence. They contain three distinct laxative components working together: insoluble fiber (bulk and stimulant), sorbitol (an osmotic sugar alcohol that draws water into the gut), and chlorogenic acid and neochlorogenic acid (phenolic compounds that appear to directly stimulate colonic motility through serotonin signaling in the gut wall).
In Chey et al.'s comparative trial, prunes at 100 g/day — approximately 10–12 prunes — produced stool frequency increases comparable to both kiwifruit and psyllium [2]. The whole-food delivery requires no supplement and provides additional nutrients. Prunes are a practical first-line option for anyone who tolerates their sweet, concentrated flavour. See our Prunes page.
Hydration and Movement
Water intake is foundational. The colon's primary function is water absorption; inadequate fluid intake means less water available in the lumen, producing drier, harder stools. Gastroenterology guidelines consistently recommend 1.5–2 litres of water daily as part of constipation management — more in hot weather or with high physical activity.
Physical activity stimulates gut motility through the gastrocolic reflex and by increasing systemic prostaglandin levels that coordinate intestinal contractions. Observational studies show a consistent inverse relationship between physical activity and constipation risk. A 30-minute daily walk is associated with measurably faster colonic transit time, particularly in previously sedentary people. See our Walking page.
When to Seek Medical Evaluation
Natural approaches work well for functional constipation. Seek medical evaluation if you experience: blood in the stool, unexplained weight loss, constipation alternating with diarrhea, new onset of constipation in someone over 50 with no prior history, or constipation that has not responded to 3–4 weeks of dietary and lifestyle measures. These warrant evaluation to rule out structural or systemic causes.
Evidence Review
Kiwifruit International Multicenter RCT (Gearry et al., 2023)
Gearry et al. (PMID 36537785) published an international multicenter RCT in the American Journal of Gastroenterology (2023) examining the effects of 2 green kiwifruits daily versus psyllium (7.5 g/day) over 4 weeks in 184 participants across three clinical groups: healthy controls (n=62), functional constipation (n=61), and IBS with predominant constipation (IBS-C, n=61). The study was conducted at sites in New Zealand, Japan, and Italy, providing meaningful cross-cultural generalizability.
Primary outcomes were complete spontaneous bowel movements per week (CSBM) and the Patient Assessment of Constipation Quality of Life (PAC-QOL) score. In the functional constipation group, kiwifruit produced a statistically significant increase in CSBM (mean increase 1.53/week, 95% CI 0.68–2.37), comparable in magnitude to psyllium. In the IBS-C group, kiwifruit produced significant improvements in abdominal comfort that marginally outperformed psyllium on that specific domain. Adverse event rates were lower in the kiwifruit group than the psyllium group across all three populations, including rates of bloating and abdominal distension.
The multinational design is a methodological strength that controls for dietary background. The open-label design is an unavoidable limitation given the intervention type — blinding participants to whether they are eating fruit or taking a supplement is not practically feasible.
Strength of evidence: High for functional constipation. International multicenter RCT with a meaningful active comparator and diverse participant population.
US Comparative Effectiveness Trial (Chey et al., 2021)
Chey et al. (PMID 34074830) published a comparative effectiveness trial in the American Journal of Gastroenterology (2021) using a crossover design to compare kiwifruit (2 green kiwifruits/day), psyllium (12 g/day), and prunes (100 g/day) in 79 US adults meeting Rome IV diagnostic criteria for chronic constipation. Participants crossed over between treatment arms with washout periods, allowing within-person comparisons that reduce confounding.
All three interventions significantly increased weekly complete spontaneous bowel movements from baseline (kiwifruit: +1.73/week; prunes: +2.23/week; psyllium: +2.05/week; all P < 0.05). Kiwifruit uniquely produced significant improvements in straining score (−0.56, P = 0.02) and stool consistency score, outcomes on which prunes and psyllium showed more modest changes. The proportion of participants reporting any digestive adverse events was lowest in the kiwifruit group, making it particularly suitable for individuals sensitive to laxative side effects.
The study population was recruited from tertiary GI centers, meaning participants may have had more severe or refractory constipation than community patients — potentially underestimating response rates achievable in general populations. Rome IV diagnostic criteria and validated constipation severity instruments (PAC-SYM) were used throughout.
Strength of evidence: High. Rigorous crossover design with active comparators, validated outcomes, and well-diagnosed constipation population.
Magnesium Oxide RCT (Mori et al., 2019)
Mori et al. (PMID 31587548) published a double-blind, placebo-controlled RCT in the Journal of Neurogastroenterology and Motility (2019) examining magnesium oxide in chronic constipation. Thirty-four women aged 18–65 with chronic constipation (Rome III criteria) were randomized to magnesium oxide 1.5 g/day or matched placebo for 28 days. Response was defined as a patient-reported improvement in overall defecation status.
Magnesium oxide achieved a 70.6% response rate versus 25.0% placebo (P < 0.01). Secondary outcomes showed stool frequency increased significantly in the magnesium group, Bristol Stool Scale scores improved from type 1–2 toward types 3–4 in most responders, and a radiopaque marker sub-study demonstrated shortening of colonic transit time. Adverse events were limited to loose stools in two participants who dose-reduced without discontinuing.
Limitations include the small sample size (n=34, all female), single-center Japanese design, and 4-week duration. The all-female enrollment limits direct extrapolation to men, though the osmotic mechanism is sex-independent. The results are consistent with the much older evidence base for magnesium hydroxide (Milk of Magnesia) and with the known role of magnesium in smooth muscle function.
Strength of evidence: Moderate. Single small RCT with strong mechanistic support and historical precedent from magnesium hydroxide literature.
Probiotics Meta-Analysis (van der Schoot et al., 2022)
Van der Schoot et al. (PMID 36372047) published a systematic review and meta-analysis in Clinical Nutrition (2022) including 30 probiotic RCTs (2,656 participants) and 4 synbiotic RCTs (303 participants) in adults with chronic constipation. Participant populations spanned general community adults, elderly individuals, pregnant women, and post-surgical patients.
For probiotics, pooled meta-analysis showed a significant increase in stool frequency of 1.3 bowel movements per week (95% CI 0.87–1.73) and a reduction in whole gut transit time of 12.4 hours (95% CI 7.2–17.6 hours). Subgroup analyses by genus showed Bifidobacterium strains produced consistently significant effects on stool frequency (SMD 0.63, 95% CI 0.36–0.90), while Lactobacillus-only strains showed heterogeneous and less consistent effects. Synbiotics (prebiotic plus probiotic) performed comparably to probiotics alone in most analyses.
The meta-analysis reported significant statistical heterogeneity (I² = 78% for stool frequency), reflecting the diversity of strains, doses, populations, and study designs. Sensitivity analyses excluding high-risk-of-bias studies maintained statistical significance, suggesting the pooled effect is robust despite heterogeneity. Head-to-head trials directly comparing Bifidobacterium strains in well-defined constipation populations would substantially strengthen strain-selection guidance.
Strength of evidence: Moderate-high. Large meta-analysis with consistent pooled effects; heterogeneity expected given strain diversity across 30 trials.
Fiber Meta-Analysis (van der Schoot et al., 2022)
Van der Schoot et al. (PMID 35816465) published a meta-analysis in the American Journal of Clinical Nutrition (2022) updating the fiber-constipation evidence base across 16 RCTs enrolling 1,251 adults with chronic constipation. Fiber types included psyllium, wheat bran, partially hydrolyzed guar gum, inulin, mixed soluble/insoluble fibers, and fiber-enriched foods.
Overall, fiber supplementation produced a response rate of 66% compared to 41% in control conditions. Psyllium showed the most consistent and statistically robust effects on both stool frequency and stool consistency. Insoluble fibers (wheat bran) were more effective for increasing stool bulk and frequency but less effective for stool consistency improvement. Mixed soluble-insoluble fiber formulations showed intermediate effects across outcomes.
Subgroup analyses identified dose-response and duration effects: trials using fiber doses above 10 g/day and lasting at least 4 weeks showed larger, more consistent responses than shorter or lower-dose interventions. Crucially, the meta-analysis found that fiber appeared less effective in participants with diagnosed slow-transit constipation (where the underlying problem is impaired colonic motor activity) compared to those with outlet dysfunction or normal-transit constipation — an important clinical qualifier for fiber-based recommendations.
Strength of evidence: High for psyllium and total fiber in normal-transit and outlet constipation. Moderate for other fiber types and reduced effectiveness in slow-transit subtypes.
References
- Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled TrialGearry R, Fukudo S, Barbara G, Kuhn-Sherlock B, Ansell J, Blatchford P, Eady S, Wallace A, Butts C, Cremon C, Barbaro MR, Pagano I, Okawa Y, Muratubaki T, Okamoto T, Fuda M, Endo Y, Kano M, Kanazawa M, Nakaya N, Nakaya K, Drummond L. American Journal of Gastroenterology, 2023. PubMed 36537785 →
- Exploratory Comparative Effectiveness Trial of Green Kiwifruit, Psyllium, or Prunes in US Patients With Chronic ConstipationChey SW, Chey WD, Jackson K, Eswaran S. American Journal of Gastroenterology, 2021. PubMed 34074830 →
- A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic ConstipationMori S, Tomita T, Fujimura K, Asano H, Ogawa T, Yamasaki T, Kondo T, Kono T, Tozawa K, Oshima T, Fukui H, Kimura T, Watari J, Miwa H. Journal of Neurogastroenterology and Motility, 2019. PubMed 31587548 →
- Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trialsvan der Schoot A, Helander C, Whelan K, Dimidi E. Clinical Nutrition, 2022. PubMed 36372047 →
- The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trialsvan der Schoot A, Drysdale C, Whelan K, Dimidi E. American Journal of Clinical Nutrition, 2022. PubMed 35816465 →
Transparency
View edit historyEvery change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.